


## Sparsentan-d<sub>5</sub>

<b>Cat. No.:</b>	HY-17621S
<b>CAS No.:</b>	1801597-09-0
<b>Molecular Formula:</b>	C <sub>32</sub> H <sub>35</sub> D <sub>5</sub> N <sub>4</sub> O <sub>3</sub> S
<b>Molecular Weight:</b>	597.78
<b>Target:</b>	Endothelin Receptor; Angiotensin Receptor; Isotope-Labeled Compounds
<b>Pathway:</b>	GPCR/G Protein; Others
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Sparsentan-d <sub>5</sub> is deuterium labeled Sparsentan. Sparsentan (RE-021) is a highly potent dual angiotensin II and endothelin A receptor antagonist with Kis of 0.8 and 9.3 nM, respectively[1].
<b>In Vitro</b>	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019;53(2):211-216.
- [2]. Murugesan N, et al. Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2'-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics. *J Med Chem.* 2005 Jan 13;48(1):171-9.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA